Navigation Links
Schering-Plough Declares Quarterly Dividends on Common Shares and 2007 Mandatory Convertible Preferred Stock
Date:6/24/2008

KENILWORTH, N.J., June 24 /PRNewswire-FirstCall/ -- The Board of Directors of Schering-Plough Corporation (NYSE: SGP) today declared a quarterly dividend of 6.5 cents per common share. Payment will be made on Aug. 26, 2008, to shareholders of record at the close of business on Aug. 1, 2008. As of March 31, 2008, there were 1,621,414,244 common shares outstanding.

The Board of Directors today also declared a quarterly dividend of $3.75 per share on the 2007 Mandatory Convertible Preferred Stock. Payment will be made on Aug. 15, 2008, to holders of record at the close of business on Aug. 1, 2008. As of March 31, 2008, there were 10,000,000 shares of 2007 Mandatory Convertible Preferred Stock outstanding.

Schering-Plough is an innovation-driven, science-centered global health care company. Through its own biopharmaceutical research and collaborations with partners, Schering-Plough creates therapies that help save and improve lives around the world. The company applies its research-and-development platform to human prescription and consumer products as well as to animal health products. Schering-Plough's vision is to "Earn Trust, Every Day" with the doctors, patients, customers and other stakeholders served by its colleagues around the world. The company is based in Kenilworth, N.J., and its Web site is http://www.schering-plough.com.


'/>"/>
SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Schering-Plough Schedules Conference Call and Webcast for 2008 Second Quarter Earnings
2. Schering-Plough Appoints Janet M. Barth Vice President, Investor Relations
3. Schering-Plough Schedules Webcast for Annual Meeting of Shareholders
4. Intervet/Schering-Plough Animal Health Outlines Strength of the Combination
5. Schering-Plough/MERCK Pharmaceuticals Receives Not-Approvable Letter from FDA for Loratadine/Montelukast
6. Schering-Plough CEO Buys $2 Million in Common Shares
7. Schering-Plough Announces Planned Divestiture of Select Animal Health Products in Europe
8. Schering-Plough Reports Financial Results for First Quarter of 2008
9. Schering-Plough Schedules Conference Call and Webcast for 2008 First Quarter Earnings
10. Schering-Plough Launches Productivity Transformation Program To Confront New Challenges
11. Centocor, Inc. and Schering-Plough Submit Application Requesting Approval of Golimumab in Europe for the Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Denville, NJ (PRWEB) January 22, 2015 ... shearing technologies such as the Bioruptor® and complete ... semi-automation system for chromatin immunoprecipitation, alleviating the need ... reagents and controls needed for ChIP of histones ...
(Date:1/22/2015)... , Jan. 22, 2015  Derma Sciences, Inc. ... company focused on advanced wound care, announces that ... tissues, have been added to the Premier, Inc. ... the opportunity for the AMNIOEXCEL® and AMNIOMATRIX® product ...
(Date:12/24/2014)... Dec. 24, 2014   BioLife Solutions , Inc. (NASDAQ: ... proprietary clinical grade hypothermic storage and cryopreservation ... for cells and tissues  ("BioLife" or the "Company"), today announced ... on May 4, 2015 (the "Annual Meeting"). Because ...
(Date:12/24/2014)... Bethesda, MD (PRWEB) December 23, 2014 ... law H.R. 83, the Omnibus and Continuing Resolution Appropriations ... hydrocephalus a condition eligible to receive funding through the ... Department of Defense (DoD). The Hydrocephalus Association (HA), working ...
Breaking Biology Technology:Diagenode Launches Unique Semi-Automated Solution for Chromatin Immunoprecipitation 2Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 2Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 3Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 5BioLife Solutions Sets Date for Annual Meeting of Stockholders 2Rare Brain Condition Now Eligible for Department of Defense Research Dollars 2
... Bio Corporation says its scientists have developed a ... ,Antibodies, naturally part of the immune system, are manufactured ... or research. Mirus' new technique, described in the February ... whose immune systems produce the antibodies that are harvested ...
... — Inacom Information Systems was awarded ... company's annual partner summit in San Diego, California. , ... campaign, which the company said drew 47 interested companies ... an implementation of wireless technology. , ,The campaign began ...
... Cyber Defense Agency, an information security consulting ... said it has been chosen to challenge eight student ... are increasing in complexity and sophistication, so it's essential ... the next generation of cyber defenders," said Sami Saydjari, ...
Cached Biology Technology:
(Date:12/19/2014)...   LaunchKey , the first decentralized mobile authentication and ... Things era, today announced the close of $3 million ... by Metamorphic Ventures with participation from ENIAC Ventures, Crosslink ... LaunchKey has raised $4 million to date, and will ...
(Date:12/17/2014)... Research and Markets ( http://www.researchandmarkets.com/research/9zq33j/global_chemical ) has ... Market 2015-2019" report to their offering. ... trend upcoming in this market is the increasing demand ... in recording of patient data for quick and correct ...
(Date:12/11/2014)... N.C. , Dec. 10, 2014  That blood pressure plays ... a while. Hypertension – the medical term for high blood ... early 1800s, and the inflatable cuff that,s used in measuring ... however, mean there,s nothing new about hypertension, its triggers and ...
Breaking Biology News(10 mins):LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4
... of deaths in the United States every year. The disease ... supply blood to the heart muscle. This occurs as a ... to progressive buildup of fatty plaque near the surface of ... month in the SIAM Journal on Applied Mathematics , ...
... Dec. 9, 2013  Bruin Biometrics, LLC ("BBI") an ... has received ISO 13485:2003 and EN ISO 13485:2012 ... System with its notified body SGS. Receipt of ... in the design, development, manufacture, and distribution of ...
... As embryonic tissue develops, cells push and pull ... for the tissue to develop properly. Now scientists at ... these forces in three-dimensional (3D) tissues and living embryos. ... lead to new tools to diagnose cancer, hypertension, connective ...
Cached Biology News:Math models enhance current therapies for coronary heart disease 2Math models enhance current therapies for coronary heart disease 3Measuring life's tugs and nudges 2Measuring life's tugs and nudges 3
Mouse anti-IkBa/MAD-3 Class: Antibody Product Group: Signalling molecules and phospho-specific Antibody...
Rabbit polyclonal to Oct2, prediluted ( Abpromise for all tested applications). entrezGeneID: 5452 SwissProtID: P09086...
Anti-Mouse Reticular Fibroblast, Purified (Clone ER-TR7) (rat IgG2a)...
Mouse monoclonal [2Q2147] to Aequorin ( Abpromise for all tested applications)....
Biology Products: